RxDoctor Payments Data

Lacey Schwanebeck, NP

Nurse Practitioner · Wisconsin Rapids, WINPI 1124793005

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.6% of the total across 330 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,627, more than ten times the $117 reported in 2021. Among nurse practitioner clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,289in general payments, 2019–2025

Across 330 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$981
  • Regeneron Healthcare Solutions, Inc.$786
  • Sanofi$674
  • Lilly USA, LLC$571
  • Amgen$542
  • UCB, Inc.$371
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$5,00195%
  • Education$2885%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,289 in reported general payments places this provider in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$203,731
Medicare patients
912
Services billed
3,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa18$389,052
OtezlaApremilast62$318,768
Dupixent PenDupilumab37$140,600
Clobetasol Propionate271$7,504
Ketoconazole379$5,551
Metronidazole78$3,418
Doxycycline Monohydrate102$3,025
Tacrolimus25$2,635
Clindamycin Phosphate71$2,278
Triamcinolone Acetonide157$1,981
Fluorouracil16$1,357
Ciclopirox43$1,213
Spironolactone36$1,209
Azelaic Acid15$1,084
Hydrocortisone179$1,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$542$318,76862 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Wisconsin Rapids

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →